Evidence map›Paper›PMID 33766089›Full record

ArticleJournal of cardiothoracic surgery2021

Impact of pre-existing comorbidities on outcomes of patients undergoing surgical aortic valve replacement - rationale and design of the international IMPACT registry.

Farhad Bakhtiary, Ali El-Sayed Ahmad, Rüdiger Autschbach, Peter Benedikt, Nikolaos Bonaros, Michael Borger, Oliver Dewald, Richard Feyrer, Hans-Joachim Geißler, Jürg Grünenfelder and 14 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of cardiothoracic surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04053088 (Surgical Aortic Valve Replacement), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04053088 active not recruitingnot on this map

Surgical Aortic Valve Replacement: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.

TypeobservationalSponsorInstitut für Pharmakologie und Präventive MedizinRan2019 to 2027Enrolled500ConditionsCardiovascular DiseasesArmsINSPIRIS RESILIA Aortic Valve™
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 4 countries.

Farhad BakhtiaryDivision of Cardiac Surgery, Heart Center Siegburg-Wuppertal, University Witten-Herdecke, Ringstr. 49, 53721, Siegburg, Germany. farhad.bakhtiary@helios-gesundheit.de.
Ali El-Sayed AhmadDivision of Cardiac Surgery, Heart Center Siegburg-Wuppertal, University Witten-Herdecke, Ringstr. 49, 53721, Siegburg, Germany.
Rüdiger AutschbachUniversity Hospital RWTH Aachen, Aachen, Germany.
Peter BenediktKepler University Hospital Linz, Linz; and Hospital Wels-Grieskirchen, Wels, Austria.
Nikolaos BonarosMedical University of Innsbruck, Innsbruck, Austria.
Michael BorgerUniversity Hospital Leipzig, Leipzig, Germany.
Oliver DewaldUniversity Hospital Oldenburg, Oldenburg, Germany.
Richard FeyrerBundeswehrzentralkrankenhaus, Koblenz, Germany.
Hans-Joachim GeißlerKepler University Hospital Linz, Linz; and Hospital Wels-Grieskirchen, Wels, Austria.
Jürg GrünenfelderHeart Clinic Hirslanden, Zurich, Switzerland.
Ka Yan LamCatharina Hospital Eindhoven, Eindhoven, The Netherlands.
Rainer LeyhUniversity Hospital Wuerzburg, Wuerzburg, Germany.
Andreas LieboldUniversity Hospital Ulm, Ulm, Germany.
Markus CzeslaHospital Passau, Passau, Germany.
Arash MehdianiUniversity Hospital Duesseldorf, Duesseldorf, Germany.
Francesco PollariCardiac Surgery, Klinikum Nürnberg - Paracelsus Medical University, Nuremberg, Germany.
Saad SalamateDivision of Cardiac Surgery, Heart Center Siegburg-Wuppertal, University Witten-Herdecke, Ringstr. 49, 53721, Siegburg, Germany.
Justus StrauchUniversity Hospital Bergmannsheil, Bochum, Germany.
Andreas VötschDepartment of Cardiovascular and Endovascular Surgery, Paracelsus Medical University, Salzburg, Austria.
Alberto WeberHeart Center Hirslanden, Zurich, Switzerland.
Daniel WendtEssen University Hospital, Essen, Germany.
Beate BottaInstitute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
Peter BramlageInstitute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.ORCID http://orcid.org/0000-0003-4970-2110
Andreas ZiererKepler University Hospital Linz, Linz; and Hospital Wels-Grieskirchen, Wels, Austria.
Kepler Universitätsklinikum · ATIPPMed (Germany) · DEKlinik Hirslanden · CHBG University Hospital Bergmannsheil Bochum · DEBundeswehrzentralkrankenhaus Koblenz · DEDüsseldorf University Hospital · DEEssen University Hospital · DEHelios Hospital Siegburg · DEInnsbruck Medical University · ATKlinikum Passau · DENuremberg Hospital · DEParacelsus Medical University · ATRadboud University Nijmegen · NLRWTH Aachen University · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Leipzig · DEUniversity Hospital Ulm · DE

Funding

Edwards Lifesciences n.a.
6 · The paper itself

Abstract

backgroundDegenerative aortic valve disease accounts for 10-20% of all cardiac surgical procedures. The impact of pre-existing comorbidities on the outcome of patients undergoing surgical aortic valve replacement (SAVR) needs further research.

methodsThe IMPACT registry is a non-interventional, prospective, open-label, multicenter, international registry with a follow-up of 5 years to assess the impact of pre-existing comorbidities of patients undergoing SAVR with the INSPIRIS RESILIA aortic valve on outcomes. IMPACT will be conducted across 25 sites in Austria, Germany, The Netherlands and Switzerland and intends to enroll approximately 500 patients. Patients will be included if they are at least 18 years of age and are scheduled to undergo SAVR with the INSPIRIS RESILIA Aortic Valve with or without concomitant ascending aortic root replacement and/or coronary bypass surgery. The primary objective is to determine all-cause mortality at 1, 3, and 5 years post SAVR. Secondary objectives include cardiac-related and valve-related mortality and structural valve deterioration including hemodynamics and durability, valve performance and further clinical outcomes in the overall study population and in specific patient subgroups characterized by the presence of chronic kidney disease, hypertension, metabolic syndrome and/or chronic inflammation. DISCUSSION: IMPACT is a prospective, multicenter European registry, which will provide much-needed data on the impact of pre-existing comorbidities on patient outcomes and prosthetic valve performance, and in particular the performance of the INSPIRIS RESILIA, in a real-world setting. The findings of this study may help to support and expand appropriate patient selection for treatment with bioprostheses.

trial registrationClinicalTrials.gov identifier: NCT04053088 .

Indexed as

ComorbidityHeart Valve Prosthesis ImplantationRegistriesTranscatheter Aortic Valve ReplacementAgedAged, 80 and overAortic ValveAortic Valve StenosisBioprosthesisCoronary Artery BypassFemaleGermanyHeart Valve ProsthesisHemodynamicsHumansInflammationAortic valve diseaseComorbiditiesReal-world settingSAVRSurgical aortic valve replacement

Identifiers

PMID33766089
PMCPMC7993500
OpenAlexW3138789838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.